CI
RARE icon

Capital International’s Ultragenyx Pharmaceutical RARE Stock Holding History

Capital International’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-30,511
Closed -$1.26M – 160
2022
Q3 		$1.26M Buy
30,511
+2,919
+11% +$150K 0.09% 147
2022
Q2 		$1.65M Sell
27,592
-1,520
-5% -$93.5K 0.12% 130
2022
Q1 		$2.11M Sell
29,112
-38,100
-57% -$2.65M 0.12% 133
2021
Q4 		$5.65M Buy
67,212
+1,978
+3% +$161K 0.29% 93
2021
Q3 		$5.88M Sell
65,234
-844
-1% -$76.3K 0.32% 84
2021
Q2 		$6.3M Sell
66,078
-340
-0.5% -$35.4K 0.35% 78
2021
Q1 		$7.56M Sell
66,418
-13,324
-17% -$1.81M 0.46% 67
2020
Q4 		$11M Buy
79,742
+1,016
+1% +$121K 0.64% 42
2020
Q3 		$6.47M Buy
78,726
+17,900
+29% +$1.48M 0.44% 62
2020
Q2 		$4.76M Hold
60,826
– – 0.45% 60
2020
Q1 		$2.7M Hold
60,826
– – 0.3% 83
2019
Q4 		$2.6M Buy
60,826
+17,905
+42% +$739K 0.27% 89
2019
Q3 		$1.84M Buy
42,921
+22,001
+105% +$1.2M 0.28% 90
2019
Q2 		$1.33M Buy
20,920
+1,494
+8% +$95.1K 0.32% 85
2019
Q1 		$1.35M Buy
19,426
+2,826
+17% +$161K 0.32% 84
2018
Q4 		$722K Hold
16,600
– – 0.2% 100
2018
Q3 		$1.27M Sell
16,600
-30,357
-65% -$2.47M 0.4% 75
2018
Q2 		$3.61M Sell
46,957
-13,700
-23% -$885K 0.63% 56
2018
Q1 		$3.09M Sell
60,657
-1,377
-2% -$69.3K 0.55% 62
2017
Q4 		$2.88M Sell
62,034
-204,466
-77% -$10M 0.55% 64
2017
Q3 		$14.2M Buy
266,500
+6,800
+3% +$403K 0.94% 45
2017
Q2 		$16.1M Buy
259,700
+52,982
+26% +$3.19M 1.07% 38
2017
Q1 		$14M Buy
206,718
+38,700
+23% +$2.95M 0.91% 40
2016
Q4 		$11.8M Buy
168,018
+11,018
+7% +$782K 0.83% 47
2016
Q3 		$11.1M Buy
+157,000
New +$10M 0.79% 49

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Capital International's RARE Position: Q4 2022 in Review

Capital International sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2022, closing a stake of 30,511 shares — an estimated $1.26M sold.

Capital International first reported a position in RARE in Q3 2016 and held it in 25 quarters. The position peaked at $16.1M in Q2 2017. 227 funds tracked by Wall St. Rank hold RARE as of Q4 2022.

  • Capital International reported no remaining Ultragenyx Pharmaceutical position as of Q4 2022 after selling out during the quarter.
  • Capital International sold 30,511 Ultragenyx Pharmaceutical shares in Q4 2022, an estimated $1.26M.
  • Capital International first reported a position in Ultragenyx Pharmaceutical in Q3 2016 and held it in 25 quarters.
  • Capital International's Ultragenyx Pharmaceutical position peaked at $16.1M in Q2 2017.
  • 227 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2022.

Based on Capital International's 13F filing for Q4 2022, filed 14 Feb 2023.